Jamie Freedman
About Jamie Freedman
Jamie Freedman, M.D., Ph.D., is Instil Bio’s Chief Medical Officer, appointed June 2, 2025, bringing 20+ years of oncology drug-development leadership across Genentech, AstraZeneca, GSK, and Merck, with a track record of 15 drug approvals spanning clinical development, medical affairs, and general management; he continues to see patients at the UCSF VA Medical Center as adjunct faculty and has led inclusive trials for underserved populations . Instil’s Q2 2025 corporate update reiterated his appointment and the company’s progress toward initiating a U.S. trial of AXN-2510, a PD‑L1×VEGF bispecific, before year-end 2025 .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Genentech | Executive roles in clinical development/medical affairs | — | Led programs through development, approval, and commercialization; cumulative 15 approvals across career |
| AstraZeneca | Oncology business leadership; medical affairs | — | Advanced oncology programs toward regulatory approvals and launches |
| GSK | Executive leadership in biopharma R&D | — | Contributed to multi-therapy area approvals and commercialization experience |
| Merck | Country-level general manager; clinical development oversight | — | Operational leadership tied to program execution and market introductions |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| UCSF VA Medical Center | Adjunct faculty; hematology/oncology clinician | — | Ongoing patient care; emphasis on health equity and inclusive trials |
Fixed Compensation
- Compensation terms (base salary, target bonus, equity grants) for Dr. Freedman were not disclosed in Instil’s 2025 and 2024 definitive proxy statements, which list named executive officers as CEO Bronson Crouch and CFO/Chief Business Officer Sandeep Laumas and do not include the CMO role .
- No Item 5.02 (executive appointment/compensation) Form 8-K was identified around the June 2, 2025 appointment; compensation details may be provided in future SEC filings (e.g., DEF 14A 2026 or a subsequent 8-K) .
Performance Compensation
| Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|
| Annual performance bonus (CMO) | — | — | — | — | — |
Not disclosed for Dr. Freedman. Company-wide, executive bonuses are structured annually against corporate goals with target percentages set by role (e.g., CEO 65%, CFO 50%), subject to Compensation Committee discretion; this reflects program design but not Jamie-specific terms .
Equity Ownership & Alignment
- Beneficial ownership, vested/unvested equity, options status, and pledging for Dr. Freedman are not disclosed in the 2025 or 2024 proxies’ ownership tables (which enumerate directors/NEOs and ≥5% holders) .
- Hedging and speculative transactions are prohibited for employees and directors under Instil’s Insider Trading and Window Period Policy .
- Dodd-Frank–compliant clawback policy applies to executive officers, enabling recoupment of erroneously awarded incentive compensation for the prior three fiscal years upon a required financial restatement .
Employment Terms
| Term | Detail |
|---|---|
| Start date | June 2, 2025 (appointment as Chief Medical Officer) |
| Contract term, severance, change-of-control | Not disclosed for Dr. Freedman. Instil’s proxies detail employment/severance terms for CEO/CFO but do not include CMO terms; a future 8-K or proxy may provide specifics . |
| Clawback/Hedging | Company-wide clawback policy and hedging prohibitions apply to executive officers |
Investment Implications
- Senior talent signal: Appointment of an experienced CMO with 15 drug approvals and multi-functional leadership suggests capability to accelerate AXN‑2510 and clinical strategy; this is a positive execution signal but depends on forthcoming U.S. trial milestones and data flow .
- Alignment and selling pressure: Absence of disclosed compensation/option grants or ownership makes it difficult to assess near-term insider selling pressure; hedging is prohibited and clawback policy reduces misalignment risk .
- Monitoring roadmap: Watch for (1) a Form 8-K Item 5.02 with employment/compensation terms, (2) Form 4 insider filings for initial grants/vesting cadence, and (3) DEF 14A 2026 for full pay-for-performance detail and ownership posture; these will clarify retention risk and incentive levers .